Affiliation:
1. Showa Pharmaceutical University
2. Division of Pharmacy, Tokai University Medical Hospital
3. Division of Hematology, Tokai University Medical Hospital
4. Division of Nursing, Tokai University Medical Hospital
Abstract
Purpose To investigate the duration of cyclophosphamide (CPA) excretion in the sweat after administration when receiving high-dose CPA therapy as a conditioning regimen for hematopoietic stem-cell transplantation (HSCT). Methods Shirts and pillowcases samples (changed once a day) from 12 patients, categorized as groups 1 (n = 6), 2 (n = 4), and 3 (n = 2), receiving high-dose CPA therapy were collected, sealed, stored at 4°C, and mailed to an analytical facility for CPA estimation using LC-MS/MS. CPA was administered intravenously at a dose of 60 mg/kg on days 1, 2 (closed-system delivery for group 3), and samples were collected during days 1–4 (groups 1,3) or days 1–9 (group 2). Results CPA was detected in all 126 shirts and pillowcases. In 9 patients, excluding 1 patient who had fever during the study period and group 3 patients, the mean (range) rate of CPA excretion in sweat was 0.03% (0.01–0.12%). The mean CPA excretion in 9 patients adjusted for body weight was 19.9 μg/kg on day 1 and 0.3 μg/kg on day 4. Conclusions This study showed that CPA was excreted for an extended duration in the patient's sweat, receiving a high-dose CPA therapy as a conditioning regimen against HSCT.
Subject
Pharmacology (medical),Oncology
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献